PADAGIS ANNOUNCES THE FIRST LAUNCH OF AN OVER-THE-COUNTER NALOXONE NASAL SPRAY IN THE UNITED STATES

08 Aug 2023
Drug Approval
ALLEGAN, Mich., Aug. 8, 2023 /PRNewswire/ -- Padagis LLC, a leading provider of specialty pharmaceuticals, has launched the country's first over-the-counter (OTC) Naloxone HCl Nasal Spray. Naloxone is a medication that is designed to rapidly reverse the effects of opioid overdose. It is a life-saving product that, until now, has only been available as a prescription-labeled drug.
PADAGIS® Naloxone HCl Nasal Spray, 4 mg, will be available on store shelves and at online retailers so that anyone can purchase it without a prescription. It contains the same active ingredient and same dose of active ingredient as NARCAN® Naloxone HCl Nasal Spray, 4 mg.
Padagis President Pamela Hoffman stated "Padagis is committed to fighting the battle against opioid overdoses and is excited to be the first to deliver naloxone nasal spray over-the-counter in the U.S. We believe this is an important step to increasing accessibility of the product and helping save lives across the country."
NARCAN® is a trademark of Emergent Operations Ireland Limited. PADAGIS® Naloxone HCl Nasal Spray and NARCAN® HCl Nasal Spray are opioid antagonists indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. PADAGIS® Naloxone HCl Nasal Spray is not a substitute for emergency medical care and repeat dosing may be necessary. Use as directed. Annual market sales for NARCAN® Naloxone HCl Nasal Spray 4mg were approximately $257 million in the 12 months ended May 2023 as measured by IQVIA.
About Padagis
Padagis is dedicated to improving the well-being of patients and consumers by providing high quality, affordable, specialized healthcare products. The company is a leading provider of extended topical and other specialty pharmaceuticals to its primary markets of the United States and Israel. Padagis employs over 1,300 people worldwide. Visit Padagis online at (http://www.padagis.com).
SOURCE Padagis
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Targets
-
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.